Stocktoria
Connect Biopharma Holdings Ltd CNTB
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-03-19
Connect Biopharma Holdings Ltd financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $64,000 | $26.0M | $0 |
| R&D expense | $37.8M | $29.3M | $53.0M |
| Operating income | -$58.1M | -$22.5M | -$69.1M |
| Income tax | $197,000 | $223,000 | $120,000 |
| Net income | -$55.5M | -$15.6M | -$62.1M |
| EPS (diluted) | $-1.00 | $-0.28 | $-1.13 |
| Operating cash flow | -$51.2M | -$23.6M | -$47.7M |
| Free cash flow | -$51.6M | -$24.4M | -$47.8M |
| Cash & equivalents | $38.3M | $78.2M | $105.7M |
| Total assets | $56.1M | $101.3M | $127.4M |
| Total liabilities | $14.1M | $9.1M | $25.9M |
| Shareholders' equity | $42.0M | $92.2M | $101.5M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | -99.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.